JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 14.35 Billion JPY | 160.91% |
| 2022 | 5.5 Billion JPY | 86.44% |
| 2021 | 2.95 Billion JPY | -43.81% |
| 2020 | 5.25 Billion JPY | 37.04% |
| 2019 | 3.83 Billion JPY | 99.22% |
| 2018 | 1.92 Billion JPY | -29.25% |
| 2017 | 2.71 Billion JPY | -12.75% |
| 2016 | 3.11 Billion JPY | 157.8% |
| 2015 | 1.2 Billion JPY | -18.35% |
| 2014 | 1.47 Billion JPY | -31.43% |
| 2013 | 2.15 Billion JPY | 15.14% |
| 2012 | 1.87 Billion JPY | 4.07% |
| 2011 | 1.8 Billion JPY | -12.86% |
| 2010 | 2.06 Billion JPY | -34.65% |
| 2009 | 3.16 Billion JPY | -0.86% |
| 2008 | 3.19 Billion JPY | -0.27% |
| 2007 | 3.19 Billion JPY | 10.3% |
| 2006 | 2.9 Billion JPY | 57.28% |
| 2005 | 1.84 Billion JPY | -47.88% |
| 2004 | 3.53 Billion JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 14.35 Billion JPY | 120.0% |
| 2024 Q2 | 12.15 Billion JPY | 12.4% |
| 2023 Q1 | 12.1 Billion JPY | 120.0% |
| 2023 Q3 | 13.6 Billion JPY | 0.0% |
| 2023 Q2 | 13.6 Billion JPY | 12.4% |
| 2023 Q4 | 14.35 Billion JPY | 5.51% |
| 2023 FY | 14.35 Billion JPY | 160.91% |
| 2022 Q2 | 4.45 Billion JPY | 45.9% |
| 2022 Q4 | 5.5 Billion JPY | 23.6% |
| 2022 FY | 5.5 Billion JPY | 86.44% |
| 2022 Q1 | 3.05 Billion JPY | 3.39% |
| 2022 Q3 | 4.45 Billion JPY | 0.0% |
| 2021 Q3 | 3.05 Billion JPY | 0.0% |
| 2021 Q4 | 2.95 Billion JPY | -3.28% |
| 2021 FY | 2.95 Billion JPY | -43.81% |
| 2021 Q1 | 5.25 Billion JPY | 0.0% |
| 2021 Q2 | 3.05 Billion JPY | -41.9% |
| 2020 Q1 | 3.7 Billion JPY | -3.42% |
| 2020 Q4 | 5.25 Billion JPY | 16.67% |
| 2020 FY | 5.25 Billion JPY | 37.04% |
| 2020 Q2 | 4.5 Billion JPY | 21.62% |
| 2020 Q3 | 4.5 Billion JPY | 0.0% |
| 2019 Q1 | 1.5 Billion JPY | -22.0% |
| 2019 FY | 3.83 Billion JPY | 99.22% |
| 2019 Q3 | 3.7 Billion JPY | 0.0% |
| 2019 Q4 | 3.83 Billion JPY | 3.54% |
| 2019 Q2 | 3.7 Billion JPY | 146.67% |
| 2018 Q1 | 1.95 Billion JPY | -28.26% |
| 2018 FY | 1.92 Billion JPY | -29.25% |
| 2018 Q4 | 1.92 Billion JPY | -1.38% |
| 2018 Q3 | 1.95 Billion JPY | 0.0% |
| 2018 Q2 | 1.95 Billion JPY | 0.0% |
| 2017 Q1 | 2.5 Billion JPY | -19.62% |
| 2017 FY | 2.71 Billion JPY | -12.75% |
| 2017 Q2 | 2.5 Billion JPY | -0.16% |
| 2017 Q4 | 2.71 Billion JPY | 8.72% |
| 2017 Q3 | 2.5 Billion JPY | 0.0% |
| 2016 Q4 | 3.11 Billion JPY | 18.82% |
| 2016 FY | 3.11 Billion JPY | 157.8% |
| 2016 Q3 | 2.62 Billion JPY | -0.32% |
| 2016 Q2 | 2.63 Billion JPY | -0.32% |
| 2016 Q1 | 2.63 Billion JPY | 118.35% |
| 2015 Q3 | 796.88 Million JPY | -5.91% |
| 2015 Q2 | 846.95 Million JPY | -0.36% |
| 2015 Q1 | 850.01 Million JPY | -42.56% |
| 2015 Q4 | 1.2 Billion JPY | 51.63% |
| 2015 FY | 1.2 Billion JPY | -18.35% |
| 2014 FY | 1.47 Billion JPY | -31.43% |
| 2014 Q4 | 1.47 Billion JPY | 88.91% |
| 2014 Q3 | 783.34 Million JPY | -7.84% |
| 2014 Q2 | 850.01 Million JPY | -9.6% |
| 2014 Q1 | 940.22 Million JPY | -56.43% |
| 2013 FY | 2.15 Billion JPY | 15.14% |
| 2013 Q1 | 822.15 Million JPY | -56.14% |
| 2013 Q2 | 972.5 Million JPY | 18.29% |
| 2013 Q3 | 897.85 Million JPY | -7.68% |
| 2013 Q4 | 2.15 Billion JPY | 140.37% |
| 2012 Q2 | 1.07 Billion JPY | 107.9% |
| 2012 Q4 | 1.87 Billion JPY | 83.51% |
| 2012 FY | 1.87 Billion JPY | 4.07% |
| 2012 Q1 | 515.2 Million JPY | -71.4% |
| 2012 Q3 | 1.02 Billion JPY | -4.64% |
| 2011 FY | 1.8 Billion JPY | -12.86% |
| 2011 Q4 | 1.8 Billion JPY | 228.2% |
| 2011 Q3 | 548.8 Million JPY | -2.97% |
| 2011 Q2 | 565.6 Million JPY | -4.33% |
| 2011 Q1 | 591.2 Million JPY | -71.4% |
| 2010 Q3 | 675.2 Million JPY | 15.54% |
| 2010 Q4 | 2.06 Billion JPY | 206.13% |
| 2010 FY | 2.06 Billion JPY | -34.65% |
| 2010 Q1 | 609.6 Million JPY | -80.73% |
| 2010 Q2 | 584.4 Million JPY | -4.13% |
| 2009 FY | 3.16 Billion JPY | -0.86% |
| 2009 Q2 | 2.98 Billion JPY | 0.0% |
| 2009 Q4 | 3.16 Billion JPY | 6.86% |
| 2009 Q3 | 2.96 Billion JPY | -0.84% |
| 2008 Q3 | 3.14 Billion JPY | 0.0% |
| 2008 Q4 | 3.19 Billion JPY | 1.32% |
| 2008 FY | 3.19 Billion JPY | -0.27% |
| 2007 FY | 3.19 Billion JPY | 10.3% |
| 2006 FY | 2.9 Billion JPY | 57.28% |
| 2005 FY | 1.84 Billion JPY | -47.88% |
| 2004 FY | 3.53 Billion JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | 15.71 Billion JPY | 8.692% |
| Astellas Pharma Inc. | 447.73 Billion JPY | 96.795% |
| Chugai Pharmaceutical Co., Ltd. | 6.48 Billion JPY | -121.451% |
| Ono Pharmaceutical Co., Ltd. | 6.55 Billion JPY | -119.017% |
| Santen Pharmaceutical Co., Ltd. | 27.46 Billion JPY | 47.748% |
| Daiichi Sankyo Company, Limited | 101.31 Billion JPY | 85.836% |
| Otsuka Holdings Co., Ltd. | 69.2 Billion JPY | 79.263% |
| Perseus Proteomics Inc. | - JPY | -Infinity% |